Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Decitabine is named as an intervention in 28 current clinical trials in our China, USA and India registers. 13 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Ruijin Hospital (7). The most-studied condition is Myelodysplastic Syndromes.

Trials by status

Recruiting1346%
Not yet open725%
Active, closed621%
By invitation27%

Trials by phase

Phase 21450%
Phase 3518%
Phase 1311%
Phase 1/227%
Phase 2/327%
Phase EARLY_PHASE114%
Phase 414%

Clinical trials of Decitabine

28 trials

Study	Phase	Status	Lead sponsor	Registers
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML NCT05586074 · ClinicalTrials.gov ↗ · Leukemia, Acute Myeloid (AML)	Phase 3	Recruiting	Sunshine Lake Pharma Co., Ltd.	China
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT NCT03793517 · ClinicalTrials.gov ↗ · Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse	Phase 2/3	Recruiting	Peking University People's Hospital	China
Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation NCT06972641 · ClinicalTrials.gov ↗ · AML, MDS	Phase 2/3	Recruiting	Ruijin Hospital	China
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML NCT02781883 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2	Recruiting	Bio-Path Holdings, Inc.	USA
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma NCT05348213 · ClinicalTrials.gov ↗ · Diffuse Large B Cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS NCT06046313 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes	Phase 2	Recruiting	First Affiliated Hospital of Zhejiang University	China
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation NCT06316960 · ClinicalTrials.gov ↗ · AML, Childhood, Relapse/Recurrence, Refractory AML	Phase 2	Recruiting	Children's Hospital of Soochow University	China
Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. NCT06393361 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	Phase 2	Recruiting	Chinese PLA General Hospital	China
CR-CHOP+X in Previously Untreated DEL NCT06701357 · ClinicalTrials.gov ↗ · DLBCL	Phase 2	Recruiting	Ruijin Hospital	China
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL NCT06803693 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma	Phase 2	Recruiting	Ruijin Hospital	China
Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome NCT04245397 · Myelodysplastic Syndromes	Phase 1	Recruiting	Syntrix Biosystems, Inc.	USA
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) NCT05190471 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory	Phase 1	Recruiting	Bio-Path Holdings, Inc.	USA
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) NCT07006025 · ClinicalTrials.gov ↗ · MDS	Phase 1	Recruiting	Treebough Therapies	USA
Evaluating the Safety and Efficacy of Decitabine in the Treatment of XMEN Patients NCT07555405 · ClinicalTrials.gov ↗ · MAGT1 Deficiency	Phase 4	Not yet open	Children's Hospital of Fudan University	China
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR NCT06297772 · ClinicalTrials.gov ↗ · AML, Adult	Phase 3	Not yet open	Ruijin Hospital	China
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. NCT06563778 · ClinicalTrials.gov ↗ · Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	Phase 2	Not yet open	Chinese PLA General Hospital	China
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients NCT07505160 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)	Phase 2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL NCT07594899 · ClinicalTrials.gov ↗ · Large B-Cell Lymphoma (LBCL)	Phase 2	Not yet open	Ruijin Hospital	China
Serplulimab Plus Decitabine and CAPOX Before Surgery for Locally Advanced Colorectal Cancer NCT07691632 · ClinicalTrials.gov ↗ · Locally Advanced Colorectal Cancer, Colorectal Adenocarcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
New Genotype-guided Treatment in Newly Diagnosed PTCL NCT07706959 · ClinicalTrials.gov ↗ · Peripheral T-cell Lymphoma (PTCL)	Phase 1/2	Not yet open	Ruijin Hospital	China
Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) NCT06499025 · ClinicalTrials.gov ↗ · AML, t(8;21), Neoantigen	Phase EARLY_PHASE1	By invitation	BGI, China	China
A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma NCT07348575 · ClinicalTrials.gov ↗ · Lymphoma, Large-Cell, Diffuse	Phase 3	By invitation	Second Affiliated Hospital of Nanchang University	China
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 NCT04229979 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 3	Active, closed	Sellas Life Sciences Group	USA, India
Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML NCT05177731 · ClinicalTrials.gov ↗ · AML, Adult, Chemotherapy Effect	Phase 3	Active, closed	Chen Suning	China
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. NCT05201066 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic	Phase 2	Active, closed	Novartis Pharmaceuticals	USA, China
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients NCT06379360 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	The First Affiliated Hospital of Soochow University	China
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML NCT06429098 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	The First Affiliated Hospital of Soochow University	China
PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes NCT06091267 · ClinicalTrials.gov ↗ · Myelodysplastic Syndromes	Phase 1/2	Active, closed	Otsuka Beijing Research Institute	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with Decitabine

30 conditions

Myelodysplastic Syndromes4Acute Myeloid Leukemia4MDS2Acute Myeloid Leukemia (AML)2Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma2AML, Adult2AML2Acute Myeloid Leukemia, in Relapse1Acute Myeloid Leukemia Refractory1Leukemia, Myelomonocytic, Chronic1Chemotherapy Effect1Diffuse Large B Cell Lymphoma1

All 30 conditions

Condition (as registered)	Trials
Myelodysplastic Syndromes	4
Acute Myeloid Leukemia	4
MDS	2
Acute Myeloid Leukemia (AML)	2
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma	2
AML, Adult	2
AML	2
Acute Myeloid Leukemia, in Relapse	1
Acute Myeloid Leukemia Refractory	1
Leukemia, Myelomonocytic, Chronic	1
Chemotherapy Effect	1
Diffuse Large B Cell Lymphoma	1
Peripheral T-cell Lymphoma (PTCL)	1
t(8;21)	1
Neoantigen	1
Stem Cell Transplant Complications	1
Leukemia, Myeloid, Acute	1
Leukemia Relapse	1
MAGT1 Deficiency	1
Lymphoma, Large-Cell, Diffuse	1
Large B-Cell Lymphoma (LBCL)	1
DLBCL	1
Diffuse Large B-Cell Lymphoma	1
AML, Childhood	1
Relapse/Recurrence	1
Refractory AML	1
Core Binding Factor Acute Myeloid Leukemia	1
Locally Advanced Colorectal Cancer	1
Colorectal Adenocarcinoma	1
Leukemia, Acute Myeloid (AML)	1

By country register

Register	Trials	Recruiting
Clinical trials in China	23	9
Clinical trials in USA	6	4
Clinical trials in India	1	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Decitabine trials

How many clinical trials are testing Decitabine?

28 current trials in our China, USA and India registers name Decitabine (also registered as 5-Aza-29-deoxycytidine) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Decitabine trials recruiting patients?

Yes. 13 of the 28 trials are recruiting: 9 with sites in China and 4 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Decitabine clinical trials?

Ruijin Hospital (7), Bio-Path Holdings, Inc (2), Chinese PLA General Hospital (2) and The First Affiliated Hospital of Soochow University (2), among 19 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Decitabine works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Decitabine works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Decitabine (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Decitabine clinical trials